KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Net Income: 2009-2024

Historic Net Income for Emergent BioSolutions (EBS) over the last 16 years, with Dec 2024 value amounting to -$190.6 million.

  • Emergent BioSolutions' Net Income fell 55.40% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.9 million, marking a year-over-year increase of 136.35%. This contributed to the annual value of -$190.6 million for FY2024, which is 74.94% up from last year.
  • Per Emergent BioSolutions' latest filing, its Net Income stood at -$190.6 million for FY2024, which was up 74.94% from -$760.5 million recorded in FY2023.
  • In the past 5 years, Emergent BioSolutions' Net Income registered a high of $305.8 million during FY2020, and its lowest value of -$760.5 million during FY2023.
  • In the last 3 years, Emergent BioSolutions' Net Income had a median value of -$211.6 million in 2022 and averaged -$387.6 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Net Income surged by 461.10% in 2020, and later tumbled by 259.40% in 2023.
  • Yearly analysis of 5 years shows Emergent BioSolutions' Net Income stood at $305.8 million in 2020, then decreased by 28.22% to $219.5 million in 2021, then plummeted by 196.40% to -$211.6 million in 2022, then slumped by 259.40% to -$760.5 million in 2023, then surged by 74.94% to -$190.6 million in 2024.